home
enabling drug discovery in the ubiquitin field since 2010
Access to well-defined and advanced ubiquitin and ubiquitin-like reagents, which could so far not be routinely produced (bio)chemically, is of paramount importance for drug development, as well as for fundamental research and structural studies. Since we founded our company in 2010, it has been well recognised by both Pharma and Academia that our products enable research in the rapidly expanding ubiquitin field. Most of the leading laboratories in the field worldwide make use of our innovative catalogue and custom reagents. We also collaborate with some outstanding scientists on research projects to further our insights in this exciting field. We are proud that our joint efforts regularly result in publications in high-ranking journals. You can find examples in the section "recent publications" below on this page. For an extensive reference list of our publications since 2010, please visit our download center.
Find out about how our reagents expedite the three stages of early drug discovery (i.e. target - lead - lead on target), by clicking on the buttons below:
target
Identify and validate your target using UbiQ Probes.
lead
Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.
lead on target
Our reagents enable you in lead on target validation and lead optimization.
target
Identify and validate your target using UbiQ Probes.
lead
Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.
lead on target
Our reagents enable you in lead on target validation and lead optimization.
reagents
UbiQ develops, manufactures and commercializes ubiquitinated peptides, ubiquitin-based reagents and high throughput assays in our own laboratory at the Amsterdam Science Park. Next to ubiquitin, we also make ubiquitin-like variants (SUMO, ISG15, NEDD8, etc) of our reagents. Important to note is that all our products are "For laboratory research use only, not for use in animals and humans".
custom made reagents
With our UbiQ technologies we are able to fully synthesize site-selective ubiquitinated peptides of native conformation, using automated solid phase peptide synthesis. This enables us to synthesize any custom made peptides.
our blog
Launch of an activity-based probe designed to selectively target USP7.
We hereby announce the launch of an activity-based probe that is designed to selectively target USP7: K58K(biotin) cRh110-Cys-Ubv(USP7)-PA (UbiQ-314). UbiQ-314 is based on Ub with the following mutations: T7D, L8Y, I13R, E34L, Q40N, L69A, and L71A....
Public-private partnership grant awarded by Health-Holland: Towards new drug therapies by a better understanding of ubiquitin metalloprotease activity.
We are happy to announce that UbiQ and Prof Titia Sixma (Netherlands Cancer Institute, Oncode Institute) were recently awarded a new public-private partnership grant by Health-Holland, which is part of the Dutch Life Sciences &...
Reagents for your SARS-CoV-2 research
Reagents for your SARS-CoV-2 research The SARS-CoV-2 coronavirus encodes a papain-like cysteine protease PLpro (NSP3) that cleaves the viral polyprotein, removes ubiquitin-like ISG15 protein modifications and (with lower activity) Lys48-linked polyubiquitin chains. As PLPro is essential for SARS-CoV-2 replication, it represents a promising target for the...
In memoriam: Professor Huib Ovaa
On the 19th of May 2020, our co-founder and dear friend Professor Dr. Huib Ovaa passed away from prostate cancer at the age of 46 years. In the past year, Huib has undergone a variety...
Public-private partnership grant by Health-Holland: New drug therapies by a better understanding of ubiquitin metalloprotease activity Tools to study ubiquitin metalloprotease activity.
17 December 2019 Public-private partnership grant awarded by Health-Holland We are happy to announce that UbiQ and Prof Titia Sixma (Netherlands Cancer Institute, Netherlands) were recently awarded a public-private partnership grant...
where to meet us
EMBO conference on Ubiquitin 2022
September 9 - 13, 2022 Cavtat, Croatia Ubiquitin and ubiquitin-like proteins in health and disease. Contact: Alfred Nijkerk (CEO)
GRK2243 Symposium, University of Würzburg (canceled due to COVID19)
May 4 - 6, 2020 Würzburg, Germany Understanding Ubiquitylation: From Molecular Mechanisms to Disease Contact: Farid El Oualid (CSO) More info conference: https://www.ubiquitin-wuerzburg-2020.de/
recent publications
Catalytic and regulatory mechanisms of the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6.
UbiQ is proud to have been part of a major collaborative research project focused on studying the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6 and whose results have been reported recently in Nature Communications. Yuan et al. Crystal...
Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites.
21st Royal Society of Chemistry - Medicinal Chemistry Symposium, 13 - 15 September 2021, Cambridge UK. Poster title: A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis. Daniel Harris (1), Dr Mads Gabrielson (2), Dr...
Anti–COVID-19 Drug Design by targeting a molecular scissor of Ubiquitin and ISG15.
UbiQ is proud to have been part of a major collaboration reported recently by Rut et al. in Science Advances, describing the activity profiling and crystal structures of inhibitor bound SARS-CoV-2 PLpro: Activity profiling and crystal...
Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex.
Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites. Leishmaniasis is a neglected tropical disease caused by parasites...
Strategy for Development of Site-Specific Ubiquitin Antibodies.
As part of collaborative research between The Netherlands Cancer Institute, Leiden University Medical Centre, UbiQ and the University of Amsterdam, van Kruijsbergen et al. report in Frontiers in Chemistry detailed protocols for the development of...